


Please type a plus sign (+) inside this box ☐

+

PTO/SB/21 (6-99)

Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/697,599
Filing Date	October 29, 2003
First Named Inventor	Austin L. GURNEY.
Group/Art Unit	1644
Examiner Name	Unassigned
Attorney Docket Number	39766-0125A

Total Number of Pages in This Submission

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
 - ☐ Fee Attached
- ☐ Amendment / Response
 - ☐ After Final
 - ☐ Version with Markings Showing Changes
 - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☒ Information Disclosure Statement and PTO-1449
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/Incomplete Application
 - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition Routing Slip (PTO/SB/69) and Accompanying Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Small Entity Statement
- ☐ Request for Refund

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Additional Enclosure(s) (please identify below):

Copy of PCT International Search Report; copies of 6 cited references submitted and a stamped return postcard.

Remarks

AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER.

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual name	Panpan Gao, Reg. No. 43,626 HELLER EHRMAN WHITE & McAULIFFE LLP
-------------------------	--

Signature

Date

January 18, 2005

Customer Number:

25213

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail" (EL 993 687 495 US) on the date indicated below and addressed to: Mail Stop: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Typed or printed name	Sandra Puljic
-----------------------	---------------

Signature

Sandra Puljic

Date

January 18, 2005

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop ___, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Austin L. GURNEY Docket No.: 39766-0125A
Serial No.: 10/697,599 Group Art Unit: 1644
Filing Date: October 29, 2003 Examiner: Unassigned
For: **INHIBITION OF IL-17 PRODUCTION**

EXPRESS MAIL LABEL NO. EL 993 687 495 US

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97

MAIL STOP: AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication, except U.S. patents and patent application publications (1276 OG 55), is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98. In addition, enclosed is a copy of the PCT International Search Report received in a related matter for the above-identified application which discloses the references cited in the attached Form PTO-1449.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. As form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.


☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
☒ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; **or**
- ☐ a fee of **\$180.00** as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of **\$0.00** and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. **08-1641 (Attorney's Docket No. 39766-0125A)**.

Respectfully submitted,

Dated: January 18, 2005

By: 
Panpan Gao (Reg. No. 43,626)

HELLER EHRMAN WHITE & MCAULIFFE LLP
275 Middlefield Road
Menlo Park, California 94025-3506
Telephone: (650) 324-7000
Facsimile: (650) 324-0638

SV 2095608 v1

INFORMATION DISCLOSURE STATEMENT PTO-1449			ATTY. DOCKET NO.: 39766-0125A		SERIAL NO.: 10/697,599	
APPLICANT : Austin L. GURNEY						
FILING DATE: October 29, 2003					GROUP: 1644	
U.S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	US 2003/012123 A1	7/3/2003	Giles-Komar, et al.	424	145.1	
FOREIGN PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						<div style="display: flex; justify-content: space-around;"> YES NO </div>
						<div style="display: flex; justify-content: space-around;"> <input type="checkbox"/> <input type="checkbox"/> </div>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	Belladonna, M. L., et al., "IL-23 and IL-21 Have Overlapping , but Distinct, Effects on Murine Dendritic Cells", The Journal of Immunology, Vol. 168, pp 5448-5454, 2002.					
	Benson, J., et al. "The Role of IL-23 in Experimental Autoimmune Encephalomyelitis", The FASEB Journal, Vol. 16, No. 5., p A1045, Abstract # 759.12, March 22, 2002.					
	Frucht, D. M., "IL-23: A Cytokine That Acts on Memory T Cells", Science's STKE, Vol. 114, pp 1-3, January 2002.					
	Oppmann, B., et al. "Novel p19 Protein Engages IL-12p40 to Form a Cytokine , IL-23 with Biological Activities Similar as Well as Distinct from IL-12, Immunity, Vol. 13, No. 5, pp 715-725, November 2000.					
	Parham, C., et al., "A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12R β 1 and a Novel Cytokine Receptor Subunit, IL-23R", Journal of Immunology, Vol. 168, pp 5699-5708, 2002.					
	Wiekowski, M. T., et al. "Ubiquitous Transgenic Expression of the IL-23 Subunit p19 Induces Multiorgan Inflammation, Runitng , Infertility, and Premature Death, Journal of Immunology, Vol. 166, pp 7563-7570, 2001.					
EXAMINER			DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.